Teva Data Shows Long-Term Benefits of AUSTEDO in Tardive Dyskinesia Treatment
Event summary
- Teva presented data from three studies at Psych Congress Elevate (June 3–6, 2026) showing long-term benefits of AUSTEDO and AUSTEDO XR in treating tardive dyskinesia (TD).
- IMPACT-TD Registry data showed AIMS score reductions in all participants with mild TD, improving daily living activities and psychosocial functioning.
- RIM-TD study found >50% of patients achieved clinically meaningful response by week 15, with additional improvements over 3 years.
- Caregiver education study revealed 53% of at-risk individuals discussed TD with providers within six months, leading to 34% receiving a diagnosis.
The big picture
Teva's latest data reinforces the long-term efficacy of AUSTEDO in managing TD, addressing a critical gap in early diagnosis and treatment. The findings come as the pharmaceutical industry increasingly focuses on real-world evidence to support drug approvals and patient care strategies. Teva's commitment to TD research positions it as a key player in neuroscience, particularly in addressing movement disorders associated with psychiatric treatments.
What we're watching
- Treatment Efficacy
- How sustained treatment with AUSTEDO will impact long-term patient outcomes in mild TD cases.
- Diagnosis Rates
- Whether caregiver education initiatives will continue to improve TD diagnosis and early intervention.
- Market Positioning
- The pace at which Teva can leverage this data to strengthen its position in the TD treatment market.
Related topics